Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas

被引:118
作者
Italiano, Antoine [2 ,4 ]
Bianchini, Laurence [2 ,4 ]
Gjernes, Elisabet [2 ,4 ]
Keslair, Frederique [2 ]
Ranchere-Vince, Dominique [5 ]
Dumollard, Jean-Marc [6 ]
Haudebourg, Juliette [3 ]
Leroux, Agnes [7 ]
Mainguene, Claire [8 ]
Terrier, Philippe [9 ]
Chibon, Frederic [1 ]
Coindre, Jean-Michel [1 ]
Pedeutour, Florence [2 ,4 ]
机构
[1] Inst Bergonie, Dept Pathol, F-33000 Bordeaux, France
[2] Univ Nice Sophia Antipolis, Lab Solid Tumors Genet, Nice, France
[3] Univ Nice Sophia Antipolis, Nice Univ Hosp, Dept Pathol, Nice, France
[4] Univ Nice Sophia Antipolis, Fac Med, CNRS, UMR 6543, Nice, France
[5] Ctr Leon Berard, Dept Pathol, F-69373 Lyon, France
[6] St Etienne Univ Hosp, Dept Pathol, St Etienne, France
[7] Ctr Alexis Vautrin, Dept Pathol, Nancy, France
[8] Princess Grace Hosp, Dept Pathol, Monaco, Monaco
[9] Inst Gustave Roussy, Dept Pathol, Villejuif, France
关键词
SQUAMOUS-CELL CARCINOMAS; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR; HUMAN SARCOMAS; P16(INK4) EXPRESSION; LUNG CANCERS; ARRAY CGH; RB; PRB; P16;
D O I
10.1158/1078-0432.CCR-08-3185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The MDM2 and HMGA2 genes are consistently amplified in well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) whereas CDK4 is frequently but not always amplified in these tumors. Our goal was to determine whether the absence of CDK4 amplification was (a) correlated to a specific clinico-histopathologic profile; and (b) compensated by another genomic anomaly involving the CCND1/CDK4/P161NK4a/RB1/E2F pathway. Experimental Design: We compared the clinical characteristics of a series of 143 WDLPS/DDLPS with amplification of both MDM2 and CDK4 (MDM2+/CDK4+) to a series of 45 WDLPS/DDLPS with MDM2 amplification and no CDK4 amplification (MDM2+/CDK4-). We used fluorescence in situ hybridization, real time quantitative reverse transcription PCR, and immunohistochemistry to explore the status of CCND1, P16INK4a, P14ARF, and RB1. Results: We found that MDM2+/CDK4- WDLPS/DDLPS represent a distinct clinical subgroup with favorable prognostic features, including low-grade lipoma-like histology, peripheral location, and lower rate of recurrence. By using fluorescence in situ hybridization, we found that genomic aberrations expected to be alternative mechanisms for compensating the lack of CDK4 amplification, such as RB1 and CDKN2A deletions or CCND1 amplification, were very uncommon. In contrast, by using real time quantitative reverse transcription PCR and immunohistochemistry, we observed that overexpression of P16INK4a (and P14ARF) and CCND1 and reduced expression of RB1 were very frequent, independently of the CDK4 status. Conclusions: Our results underscore the complex coordinated regulation of the RB and p53 growth-control pathways in WDLPS/DDLPS. Because the absence of CDK4 amplification is not specifically counterbalanced by a genomic alteration of the CCND1/CDK4/P16INK4a/RB1/E2F pathway, CDK4 amplification may only represent a "MDM2-HMGA2-helper" in WDLPS/DDLPS tumorigenesis. (Clin Cancer Res 2009;15(18):5696-703)
引用
收藏
页码:5696 / 5703
页数:8
相关论文
共 50 条
[1]   The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention [J].
Alao, John P. .
MOLECULAR CANCER, 2007, 6 (1)
[2]   p14ARF links the tumour suppressors RB and p53 [J].
Bates, S ;
Phillips, AC ;
Clark, PA ;
Stott, F ;
Peters, G ;
Ludwig, RL ;
Vousden, KH .
NATURE, 1998, 395 (6698) :124-125
[3]   Linking cyclins to transcriptional control [J].
Coqueret, O .
GENE, 2002, 299 (1-2) :35-55
[4]  
de Castro I.Perez., 2008, CURR OPIN PHARMACOL, V8, P375, DOI DOI 10.1016/j.coph.2008.06.013
[5]  
Dong YY, 2001, INT J CANCER, V95, P209, DOI 10.1002/1097-0215(20010720)95:4<209::AID-IJC1036>3.0.CO
[6]  
2-R
[7]   The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression [J].
Ferru, A. ;
Fromont, G. ;
Gibelin, H. ;
Guilhot, J. ;
Savagner, F. ;
Tourani, J. M. ;
Kraimps, J. L. ;
Larsen, C. J. ;
Karayan-Tapon, L. .
BRITISH JOURNAL OF CANCER, 2006, 95 (12) :1670-1677
[8]  
Fletcher CDM, 2002, WORLD HLTH CLASSIFIC
[9]   Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas -: a possible mechanism for altering the nm23-H1 activity [J].
Forus, A ;
D'Angelo, A ;
Henriksen, J ;
Merla, G ;
Maelandsmo, GM ;
Florenes, VA ;
Olivieri, S ;
Bjerkehagen, B ;
Meza-Zepeda, LA ;
Blanco, FD ;
Müller, C ;
Sanvito, F ;
Kononen, J ;
Nesland, JM ;
Fodstad, O ;
Reymond, A ;
Kallioniemi, OP ;
Arrigoni, G ;
Ballabio, A ;
Myklebost, O ;
Zollo, M .
ONCOGENE, 2001, 20 (47) :6881-6890
[10]   Roles of HMGA proteins in cancer [J].
Fusco, Alfredo ;
Fedele, Monica .
NATURE REVIEWS CANCER, 2007, 7 (12) :899-910